The group of Japanese scientists announced on Friday the transplantation-induced pluripotent stem cells (iPS) of Parkinson's disease in the patient's brain, which is the first such experiment in the world.
The Kyoto University Director points to 2.4 million iPS cells –which can produce all types of cells– left brain for three hours in October.
Male, about 50 years old, He took care well and remained under supervision for two years, said at the Kyoto University in his statement.
If the problem occurs within the next six months, scientists implanted 2.4 million additional tissues, this time in the right part of the brain.
These healthy donors iPS cells are supposed to develop into neurons that produce dopamine, a neurotransmitter involved in engine control.
The University of Kyoto announced in July that it will conduct clinical research between seven people aged 50-69.
Parkinson's disease is characterized neuronal degeneration, symptoms that gradually exacerbate such as tremor, muscle stiffness, and impaired body movement.
It affects over ten million people in the world, according to the American Parkinson's Disease Foundation. The currently available therapies "improve the symptoms without slowing the progression of the disease", explains the basis.
New studies are trying to turn evil.
Prior to clinical trials, humans were subjected to monkeys of human stem cells to improve the exposure of Parkinson's type primates in a study published in August 2017 in Nature.
For two years the survival rate of cells transferred was closely monitored by injection within the primate brain and no tumor was observed.
Induced pluripotent stem cells (iPSs) are adult cells reduced to their quasi-embryo state to form four genes (normally inactive for adults). This genetic manipulation restores the ability to produce any cell according to the location of the body where they are transplanted.
The use of IPS cells does not cause significant ethical problems, unlike human embryonic stem cells.